peptide wiki

Mechanism

Three-way pre-mixed blend combining two tissue-repair peptides with an anti-inflammatory tripeptide. BPC-157 is a synthetic pentadecapeptide studied in animals for tendon, ligament, and GI healing via angiogenesis (VEGFR2). TB-500 is a synthetic fragment of Thymosin beta-4 that promotes actin regulation, cell migration, and angiogenesis in tissue-repair models. KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH and acts as an NF-kB-inhibiting anti-inflammatory. None of the three components is FDA-approved for human therapeutic use, and there are no controlled human efficacy or safety trials for this specific three-component combination; the rationale is inferred from individual grey-market research peptides.

Studied uses

• musculoskeletal and soft-tissue injury recovery (research only)
• combined tissue repair plus inflammation control (research only)
• post-injury recovery stacking (research only)

Identification

Typical dose	Vendor-dependent; component norms: BPC-157 250-500 mcg/day subcutaneous; TB-500 2-5 mg/week subcutaneous; KPV 200-500 mcg/day. No validated combination dosing exists.
Half-life	BPC-157: disputed (under 30 minutes per most data); TB-500: ~2 hours plasma; KPV: short and not well characterized in humans

Safety

Not FDA-approved for human therapeutic use; sold as a research-only / grey-market blend. No combination-specific human safety data; risks are extrapolated from limited research on the individual components. Not evaluated by WADA as a blend.